top of page
XeroThera Logo 1.png


Synthetic Grafts

Controlled Release  

XT Logo 2_edited.png

About Us

XeroThera has developed breakthrough technologies for tissue engineering and the controlled and targeted delivery of drugs and biological molecules. The technology is the result of twenty years of fundamental studies on sol gel processed, nanoporous, oxide-based materials in academic laboratories at the University of Pennsylvania, Philadelphia.


XeroThera’s unique delivery concepts make it possible to treat conditions that currently defy solutions. It has formulated a pipeline of product concepts that address the prevention and treatment of surgical infections, bone infections, and resistant (“MRSA”) infection; it can also develop tissue engineering scaffolds, and address surgical pain treatment and diabetes wound treatment. 

Home: Homepage_about

Paul Ducheyne, PhD

Chairman, Board of Directors, and CEO

XeroThera is led by a seasoned entrepreneur. Dr. Paul Ducheyne previously founded Orthovita, and was Chairman of the Board of Directors through its IPO. This NASDAQ-listed company was acquired by Stryker in 2011. He has more than 30 years of scientific, technical, entrepreneurial, and governance experience in biomaterials, medical devices, tissue engineering, and controlled release fields, especially as it concerns orthopedics, but also as it relates to cardiology, dentistry, and medicine.

David Joseph, MBA

President and Member, Board of Directors

Mr. Joseph has over forty years of healthcare and life science management; co-founder and CEO of five companies in medical technology, biomaterials and biopharmaceuticals, most recently as President and CEO of AVISA Pharma.  Mr. Joseph served as Chairman and CEO of Othera Pharmaceuticals and co-founder  of Orthovita Inc, where he served as President and CEO.  Orthovita was acquired by Stryker in 2012.  Prior to Orthovita, Mr. Joseph co-founded two medical device companies: Surgical Laser Technologies, Inc., which became public in 1989 and SITE Microsurgical Systems, which was acquired by Johnson & Johnson Corporation in 1983. Mr. Joseph received the Greater Philadelphia Venture Group’s Raymond Rafferty Entrepreneurial Excellence Award in May 2005 for having founded four successful venture-backed companies and for his influence on the ophthalmic and medical technology industries.

Jonathan Garino, MD, MBA

Member, Board of Directors

Jonathan Garino, co-Founder of XeroThera, is a practicing physician, and obtained the M.B.A. degree. He currently is a Clinical Professor of Orthopedic Surgery at Thomas Jefferson Medical College, Philadelphia, is the former director of the Adult Reconstruction Center at the Hospital of the University of Pennsylvania, Philadelphia. He is a national and international expert in hip and knee replacements having participated in numerous scientific studies including 6 IDE trials for ceramic bearings, contributing significantly to bringing this technology to the US market. 

Sanjib Bhattacharyya, PhD

Vice President of R&D 

Dr. Bhattacharyya’s knowledge of materials chemistry, sol gel science, surface functionalization and biomaterials science is profound and cutting edge. He has presented his ground breaking work at many international scientific conferences. In conjunction with the VP for Manufacturing Operations he will be implementing and managing the upscaling of the material concepts for production, and develop the internal research program.

Charles Cohen, Ph.D

Vice President, Product Development

Charles Cohen is a seasoned biomedical entrepreneur with expertise in applying biomedical technology to commercial opportunity. Previously, Dr. Cohen was the CTO of Polymer Therapeutics which developed novel biomaterial based antimicrobial therapies for prophylactic treatment of surgical site infections.  Dr. Cohen was also a co-founder of Orthovita and directed the Oral, Cranial, and Facial Reconstruction business until the entire product line was sold in a strategic divestiture. Subsequently, Dr Cohen co-founded Gentis and served as its Vice President of Product Development and was a co-inventor for the patents surrounding Gentis’ key technology for treating degenerated or herniated discs in the spine.

Home: TeamMember


Nano-Structered XeroGels are easily produced from non-toxic and safe precursors of Silica as well as other natural elements such as Calcium and Phosphate which can be added for optimization in hard tissue applications. These highly porous scaffolds have unique characteristics for tissue engineering and sustained delivery of pharmaceutical and biological molecules.  Differentiating characteristics of the technology are:

  • Room temperature fabrication safe for all pharmaceutical molecules, including antibiotics and growth factors

  • Biocompatible and resorbable 

  • Formation of Ca-P surface layer in vivo compatible with bone growth and repair processes

  • Tunable sustained delivery of bioactive molecules from hours to days, weeks, and beyond…

  • Pharmaceutical products can be added at the time of surgery

XeroGel Micro 2 copy.png

Nano-Particle Precision

Precise control over the structure and properties of XeroGel materials allows for the incorporation of a variety of biological molecules.  Fragile molecules are well protected once they are incorporated into the oxide matrix, thus allowing molecules with a short half-life or large fragile bioengineered molecules to be incorporated and released in a controlled, safe, and predictable process.

Home: Feature

Product Pipeline


  • Microparticle for surgical use


  • Universal, injectable nanoparticle, formulated to treat MRSA

  • Regulatory pathway (US): Qualified Infectious Disease Product (QIDP)

> Eligible for fast track designation

> Priority review for marketing  applications

> Additional 5  years  exclusivity granted at time of approval


  • Micron thin films on implants for continuous local delivery of bactericidal molecules

  • Unique product concept for strategic partnering

  • Extensive preclinical studies as a basis for regulatory review

Home: About
Home: Contact

Enterprise Building

  • Focus on product with short duration to market (XeroSyn™)

  • Control core technology

  • Develop manufacturing capabilities

  • Advance XeroSyn™ towards the clinic; generate sales

  • Develop strategic partnerships with a large company from

         > the device field (XeroSyn™, XeroMicron™)

         > the pharmaceutical/ biotech field (XeroDuo™)

  • Leverage patent portfolio

  • Establish presence in both US and Europe


Press Releases

January 16, 2023:

David Joseph Joins XeroThera as President                                                             Read More


Contact Us

Your details were sent successfully!

bottom of page